Get the Stockscreener App
15.91
9.45%
-1.66
After Hours:
15.79
-0.12
-0.75%
Seres Therapeutics Inc stock is traded at $15.91, with a volume of 807.24K.
It is down -9.45% in the last 24 hours and up +3.04% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$17.57
Open:
$17.27
24h Volume:
807.24K
Relative Volume:
4.90
Market Cap:
$139.29M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-795.50
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
-17.82%
1M Performance:
+3.04%
6M Performance:
+14.76%
1Y Performance:
-17.14%
1-Day Range:
$14.22
$17.75
1-Week Range:
$14.22
$24.67
52-Week Range:
$6.53
$24.67
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
15.91 | 153.99M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Will Seres Therapeutics Inc. stock outperform Nasdaq indexShort Setup & Advanced Swing Trade Entry Plans - baoquankhu1.vn
What’s next for Seres Therapeutics Inc. stockProfit Target & Low Risk High Reward Ideas - Lancaster City Council
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy - Yahoo Finance
Is Seres Therapeutics Inc. in a bullish channelJuly 2025 Market Mood & Free Technical Confirmation Trade Alerts - Lancaster City Council
Biotech Stocks Surge After Hours: CAPR, TMDX Lead Gains Amid Trial Updates And Earnings Momentum - RTTNews
Is It Too Early to Call Recovery in Seres Therapeutics Inc.Watch List & High Win Rate Trade Tips - beatles.ru
Seres Therapeutics (MCRB) Surges on Nestlé's $760 Million Offer - GuruFocus
Seres Therapeutics soars on report of takeover offer - MSN
Seres Therapeutics soars on report of takeover offer (MCRB:NASDAQ) - Seeking Alpha
Premarket Movers: RAPP, MCRB, JAGX. MEIP… - RTTNews
Seres Therapeutics Inc. Added to High Probability Setup ListWeekly Stock Summary & Low Volatility Stock Recommendations - beatles.ru
Charles Schwab Investment Management Inc. Sells 31,718 Shares of Seres Therapeutics, Inc. $MCRB - MarketBeat
Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross - MSN
Seres Therapeutics Inc. stock outlook for YEAR2025 Retail Activity & Safe Investment Capital Preservation Plans - Newser
Evaluating Seres Therapeutics Inc. with trendline analysisDividend Hike & Reliable Trade Execution Plans - Newser
tick level data insight on seres therapeutics inc. volatility2025 Top Gainers & AI Enhanced Trading Alerts - Newser
What candlestick patterns are forming on Seres Therapeutics Inc.Weekly Gains Summary & Growth Oriented Trading Recommendations - Newser
Is it time to cut losses on Seres Therapeutics Inc.July 2025 Highlights & Daily Stock Trend Watchlist - Newser
Ranking Seres Therapeutics Inc. among high performing stocks via tools2025 Volatility Report & Free Technical Confirmation Trade Alerts - Newser
Pattern recognition hints at Seres Therapeutics Inc. upsideMarket Sentiment Summary & Stepwise Entry/Exit Trade Alerts - Newser
Visual analytics tools that track Seres Therapeutics Inc. performanceJuly 2025 Rallies & High Yield Stock Recommendations - Newser
Using Bollinger Bands to evaluate Seres Therapeutics Inc.Day Trade & Free Weekly Watchlist of Top Performers - Newser
How to read the order book for Seres Therapeutics Inc.Earnings Overview Report & Technical Pattern Based Signals - Newser
Volume spikes in Seres Therapeutics Inc. stock – what they mean2025 Market Outlook & Fast Entry and Exit Trade Plans - Newser
Is There Enough Volume to Lift Seres Therapeutics Inc.July 2025 Outlook & Real-Time Buy Zone Alerts - beatles.ru
Has Seres Therapeutics Inc. formed a bullish divergenceIndex Update & Long-Term Growth Plans - Newser
Seres Therapeutics receives $50 million from Nestlé Health Science - MSN
Earnings visualization tools for Seres Therapeutics Inc.2025 Short Interest & Target Return Focused Stock Picks - Newser
What machine learning models say about Seres Therapeutics Inc.2025 Volatility Report & Stepwise Swing Trade Plans - Newser
Seres Therapeutics Inc. stock momentum explainedJuly 2025 Closing Moves & Verified Momentum Stock Ideas - Newser
How to integrate Seres Therapeutics Inc. into portfolio analysis tools - Newser
Is Seres Therapeutics Inc. still worth holding after the dipEarnings Beat & Verified High Yield Trade Plans - Newser
Tick level data insight on Seres Therapeutics Inc. volatilityJuly 2025 Drop Watch & Community Shared Stock Ideas - Newser
Is now a turning point for Seres Therapeutics Inc.July 2025 Analyst Calls & Daily Oversold Stock Bounce Ideas - Newser
Full technical analysis of Seres Therapeutics Inc. stock2025 Technical Patterns & Free Expert Approved Momentum Trade Ideas - Newser
Can Seres Therapeutics Inc. be the next market leaderPortfolio Value Report & Fast Moving Stock Watchlists - خودرو بانک
Custom strategy builders for tracking Seres Therapeutics Inc.Sell Signal & Stock Market Timing Techniques - Newser
Is Seres Therapeutics Inc. a good stock for dollar cost averaging2025 Macro Impact & Precise Swing Trade Entry Alerts - خودرو بانک
Is Seres Therapeutics Inc. affected by consumer sentimentTrend Reversal & Weekly High Return Stock Opportunities - خودرو بانک
What MACD signals say about Seres Therapeutics Inc.Gold Moves & Long-Term Growth Portfolio Plans - Newser
Statistical indicators supporting Seres Therapeutics Inc.’s strength2025 Support & Resistance & Stock Market Timing Techniques - Newser
Top chart patterns to watch in Seres Therapeutics Inc.July 2025 Review & Weekly Watchlist for Consistent Profits - Newser
What is Seres Therapeutics Inc. s debt to equity ratioQuarterly Earnings Summary & Weekly Hot Stock Watchlists - خودرو بانک
What moving averages say about Seres Therapeutics Inc.July 2025 Market Mood & AI Forecasted Stock Moves - Newser
Market Pulse: Is Seres Therapeutics Inc. backed by strong institutional buyingTrade Analysis Report & Target Return Focused Picks - خودرو بانک
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):